Summary of significant transactions - Clinical collaboration agreement with Adaptimmune (Details) - Adaptimmune Collaboration [member] - USD ($) |
12 Months Ended | |
|---|---|---|
May 30, 2024 |
Dec. 31, 2024 |
|
| Summary Of Significant Transaction [line items] | ||
| Upfront Exclusivity Payment | $ 70,000,000 | |
| Research And Development Payment | $ 15,000,000 | |
| Upfront Exclusive Research And Development Payable | $ 15,000,000 | |
| Intangible assets capitalised | 70,000,000 | |
| Deferred Expenses | 15,000,000 | |
| First Payment [member] | ||
| Summary Of Significant Transaction [line items] | ||
| Upfront Exclusivity Payment | 70,000,000 | |
| Second Payment [member] | ||
| Summary Of Significant Transaction [line items] | ||
| Research And Development Payment | $ 15,000,000 |